deltatrials

Ipsen Clinical Trials

Sponsors / Ipsen

ClinicalTrials.gov lists 320 trials for which Ipsen is named as lead sponsor. Of these, 27 are recruiting, 18 are active without new recruitment, and 222 have completed. The registry records 46 terminated or withdrawn trials for Ipsen. The most common reasons cited for termination include slow or insufficient recruitment, safety concerns. Planned participant enrollment across these trials sums to 68,987. Figures on this page are sourced from ClinicalTrials.gov and refreshed with each registry update.

320
Total Trials
27
Recruiting
18
Other Active
222
Completed
46
Terminated / Withdrawn
68,987
Total Enrollment

Termination reasons: Other39% · Recruitment37% · Safety11% · Efficacy7% · Business4% · Funding2%

Recent Terminations

  • NCT03736720 Phase PHASE2 Stopped Aug 2024
    Locally Advanced Digestive System Neuroendocrine Carcinoma
    "low accrual"
  • NCT05922579 Stopped Dec 2023
    Neuroendocrine Tumors
    "Significant and complex challenges had since been identified during recent testing phases. After their assessment, Ipsendecided to discontinue development of this motorized device in order to not burden participants."
  • NCT04736745 Phase PHASE1 Stopped Oct 2022
    Moderate Upper Facial Lines
    "Sponsor terminated the study due to strategic considerations"
  • NCT03947762 Stopped Apr 2021
    Pancreatic Neuroendocrine Tumor
    "Low enrollment"
  • NCT03525392 Phase PHASE1 Stopped Apr 2021
    Advanced Cancer
    "Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns"
  • NCT03598777 Phase PHASE2 Stopped Jan 2021
    Vulvodynia
    "lack of efficacy"
  • NCT03894540 Phase PHASE1 Stopped Dec 2020
    Solid Tumor
    "Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090"
  • NCT03729297 Phase PHASE2 Stopped Nov 2019
    Salivary Gland Cancer
    "safety issues"
  • NCT03773133 Phase PHASE1/PHASE2 Stopped Oct 2019
    Small Cell Lung Cancer and Breast Cancer
    "High number of screen failures"
  • NCT03697551 Phase PHASE2 Stopped Feb 2019
    Breast Cancer
    "Recruitment challenges and not due to safety concerns."

Active Trials (18 total)

Top Conditions

Top Locations